Comparative Pharmacology
Head-to-head clinical analysis: ORAP versus PERMITIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ORAP versus PERMITIL.
ORAP vs PERMITIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Orap (pimozide) is a diphenylbutylpiperidine antipsychotic that selectively blocks dopamine D2 receptors in the central nervous system, with weak antagonism at alpha1-adrenergic and H1-histamine receptors. Its anti-dyskinetic effect in Tourette syndrome may also involve blockade of calcium channels.
Antagonist at dopamine D2 receptors, also blocks alpha-1 adrenergic, histaminergic, and muscarinic receptors.
Initial: 2 mg orally twice daily; maintenance: 2-10 mg twice daily. Maximum 20 mg/day.
2.5-10 mg orally every 8-12 hours; maximum 40 mg/day. For severe psychosis: initial 10 mg IM, then 5-10 mg IM every 6-8 hours; maximum 30 mg/day IM.
None Documented
None Documented
Clinical Note
moderateVorapaxar + Tranilast
"Vorapaxar may increase the anticoagulant activities of Tranilast."
Clinical Note
moderateVorapaxar + Resveratrol
"Vorapaxar may increase the anticoagulant activities of Resveratrol."
Clinical Note
moderateVorapaxar + Nimesulide
"Vorapaxar may increase the anticoagulant activities of Nimesulide."
Clinical Note
moderateVorapaxar + Epoprostenol
"Vorapaxar may increase the antiplatelet activities of Epoprostenol."
Terminal elimination half-life is 20–40 hours (mean 27 hours). Steady-state achieved in 4–7 days.
Terminal elimination half-life: 20-30 hours; clinically, steady-state achieved in 5-7 days; prolonged in elderly and hepatic impairment
Primarily hepatic metabolism; approximately 40% excreted in urine as metabolites, 15% in feces as unchanged drug and metabolites.
Renal: <1% unchanged; Hepatic: extensively metabolized, metabolites excreted in urine (50-60%) and feces (30-40%)
Category C
Category C
Antipsychotic
Antipsychotic